• 검색 결과가 없습니다.

Author correction

N/A
N/A
Protected

Academic year: 2022

Share "Author correction"

Copied!
1
0
0

로드 중.... (전체 텍스트 보기)

전체 글

(1)

www.ogscience.org 621

Erratum

Obstet Gynecol Sci 2017;60(6):621 https://doi.org/10.5468/ogs.2017.60.6.621 pISSN 2287-8572 · eISSN 2287-8580

Author correction

Young-Jae Lee, Yong-Man Kim, Hyun Jin Kim, Sung Wook Choi, Shin-Wha Lee, Jeong-Yeol Park, Dae-Yeon Kim, Dae-Shik Suh, Jong-Hyeok Kim, Young-Tak Kim, Joo-Hyun Nam

In the published article, “Young-Jae Lee, Yong-Man Kim, Shin-Wha Lee, Jeong-Yeol Park, Dae-Yeon Kim, Dae- Shik Suh, Jong-Hyeok Kim, Young-Tak Kim, Joo-Hyun Nam. The efficacy and safety of pegylated liposomal doxorubicin monotherapy and combination therapy with carboplatin in Korean patients with recurrent ovarian, fallopian tube, or primary peritoneal cancer: a single-institution experience. Obstet Gynecol Sci 2017;60(5):433- 439. https://doi.org/10.5468/ogs.2017.60.5.433,” the author was published incorrectly. The Editorial Office of Obstet Gynecol Sci would like to correct the author list. The Editorial Office apologizes for any inconvenience that it may have caused.

Young-Jae Lee, Yong-Man Kim, Shin-Wha Lee, Jeong-Yeol Park, Dae-Yeon Kim, Dae-Shik Suh, Jong-Hyeok Kim, Young-Tak Kim, Joo-Hyun Nam

The author list should be corrected as follows. Changes are marked by underlines:

Young-Jae Lee, Yong-Man Kim, Hyun Jin Kim, Sung Wook Choi, Shin-Wha Lee, Jeong-Yeol Park, Dae-Yeon Kim,

Dae-Shik Suh, Jong-Hyeok Kim, Young-Tak Kim, Joo-Hyun Nam

참조

관련 문서

Therefore, our aim in this study was to compare the efficacy of daily 20 mg rosuvastatin monotherapy with that of daily 5 mg rosuvastatin/10 mg ezetimibe combination therapy daily